NCT04905407 2025-02-24
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals
Phase 2 Terminated
Clinical Trials
4 trialsNCT02807558 2024-12-13
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
Phase 2 Completed
NCT01337154 2013-06-28
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
CytRx
Phase 2 Terminated
NCT00520208 2013-02-13
STAR-1
CytRx
Phase 2 Completed